These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1884741)

  • 21. Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children.
    Mawatari H; Unei K; Nishimura S; Sakura N; Ueda K
    Pediatr Int; 2001 Dec; 43(6):673-7. PubMed ID: 11737747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
    Landier W; Hageman L; Chen Y; Kornegay N; Evans WE; Bostrom BC; Casillas J; Dickens DS; Angiolillo AL; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
    J Clin Oncol; 2017 May; 35(15):1730-1736. PubMed ID: 28339328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia.
    Hale JP; Lilleyman JS
    Arch Dis Child; 1991 Apr; 66(4):462-6. PubMed ID: 2031601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.
    Lennard L; Lilleyman JS; Van Loon J; Weinshilboum RM
    Lancet; 1990 Jul; 336(8709):225-9. PubMed ID: 1973780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extremely low dose of 6-mercaptopurine in a Chinese child with acute lymphoblastic leukaemia and multiple pharmacogenetic mutations.
    Zhai XY; Zhou Y; Dong L; Nie AQ; Zhi LJ; Jacqz-Aigrain E; Wang TY; Wang L; Zhao W
    J Clin Pharm Ther; 2021 Feb; 46(1):74-77. PubMed ID: 32893890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.
    Koren G; Langevin AM; Olivieri N; Giesbrecht E; Zipursky A; Greenberg M
    Am J Dis Child; 1990 Oct; 144(10):1135-7. PubMed ID: 2403095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cranial irradiation and cerebrospinal fluid levels of 6-mercaptopurine in children with acute leukemia.
    Riccardi R; Lasorella A; Tartaglia RL; Riccardi A; Servidei T; Mastrangelo R
    Med Oncol Tumor Pharmacother; 1991; 8(2):95-8. PubMed ID: 1749306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compliance with oral chemotherapy in childhood lymphoblastic leukaemia.
    Davies HA; Lilleyman JS
    Cancer Treat Rev; 1995 Mar; 21(2):93-103. PubMed ID: 7758006
    [No Abstract]   [Full Text] [Related]  

  • 30. 6-Mercaptopurine in cerebrospinal fluid during oral maintenance therapy of children with acute lymphoblastic leukemia.
    Hayder S; Lafolie P; Björk O; Ahström L; Peterson C
    Med Oncol Tumor Pharmacother; 1988; 5(3):187-9. PubMed ID: 3166086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics.
    Koren G; Solh H; Klein J; Soldin SJ; Greenberg M
    Med Pediatr Oncol; 1989; 17(6):450-4. PubMed ID: 2586358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection and identification of 6-methylmercapto-8-hydoxypurine, a major metabolite of 6-mercaptopurine, in plasma during intravenous administration.
    Keuzenkamp-Jansen CW; van Baal JM; De Abreu RA; de Jong JG; Zuiderent R; Trijbels JM
    Clin Chem; 1996 Mar; 42(3):380-6. PubMed ID: 8598099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of 6-mercaptopurine in acute lymphoblastic leukemia patients' plasma by high-performance liquid chromatography.
    Kato Y; Matsushita T; Yokoyama T; Mohri K
    Ther Drug Monit; 1991 May; 13(3):220-5. PubMed ID: 1926275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
    Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
    Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
    Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia.
    Schmiegelow K; Bruunshuus I
    Cancer Chemother Pharmacol; 1990; 26(4):288-92. PubMed ID: 2369793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?
    Lennard L; Welch J; Lilleyman JS
    Br J Cancer; 1995 Oct; 72(4):1004-6. PubMed ID: 7547211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.
    Lennard L; Welch J; Lilleyman JS
    Br J Clin Pharmacol; 1996 Oct; 42(4):525-7. PubMed ID: 8904630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine.
    Balis FM; Holcenberg JS; Zimm S; Tubergen D; Collins JM; Murphy RF; Gilchrist GS; Hammond D; Poplack DG
    Clin Pharmacol Ther; 1987 Apr; 41(4):384-7. PubMed ID: 3470165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of oral 6-mercaptopurine: relationship between plasma levels and urine excretion of parent drug.
    Endresen L; Lie SO; Storm-Mathisen I; Rugstad HE; Stokke O
    Ther Drug Monit; 1990 May; 12(3):227-34. PubMed ID: 2349605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.